<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03711214</url>
  </required_header>
  <id_info>
    <org_study_id>IPS - pSS</org_study_id>
    <secondary_id>2015/03756-4</secondary_id>
    <secondary_id>2018/09937-9</secondary_id>
    <nct_id>NCT03711214</nct_id>
  </id_info>
  <brief_title>Immune Profile of Saliva and Serum of Patients With Primary Sjögren´s Syndrome</brief_title>
  <acronym>pSS</acronym>
  <official_title>Analysis of the Immune Profile of Saliva and Serum of Patients With Primary Sjögren´s Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Sjögren's syndrome (pSS) is a chronic systemic inflammatory disease, which mainly&#xD;
      affects the lacrimal and salivary glands, leading to sicca syndrome. pSS has a probable&#xD;
      autoimmune etiology, with the production of several autoantibodies such as antinuclear&#xD;
      antibodies (ANA), anti-Ro/SS-A, anti-La/SS-B, rheumatoid factor (RF) and cryoglobulins.&#xD;
      Recently, our group described a high frequency of antibodies directed to DNase I in the serum&#xD;
      of pSS patients and these antibodies were associated with the presence of the&#xD;
      anti-Epstein-Barr (EBV) early antigen diffuse (anti-EA-D). This finding becomes interesting&#xD;
      considering the recent description of reduction of DNase I activity in the tear of patients&#xD;
      with xerophthalmia of different causes, which would result in an accumulation of&#xD;
      extracellular DNA and neutrophilic inflammatory infiltrate on the ocular surface. This&#xD;
      hypothesis is reinforced by the observation that treatment with DNase I as eye drops results&#xD;
      in clinical improvement of dry eye. In addition, it has been shown that periodontal disease&#xD;
      is an aggravating factor of xerostomia in pSS, as it leads to a chronic inflammatory process&#xD;
      and, consequently, to the destruction of minor salivary glands. Therefore, the objective of&#xD;
      the present study will be to evaluate the presence of antibodies directed to DNase I in the&#xD;
      saliva and serum of pSS patients and its possible capacity of inhibition of the enzyme before&#xD;
      and after treatment of periodontal disease. Such findings will be correlated with the&#xD;
      presence of periodontal disease, with the glandular and extraglandular manifestations of SSp&#xD;
      and also with the presence of EBV DNA in the serum and oral lavage of these patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Actual">October 13, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Clinical treatment of periodontal disease in pSS patients and healthy individuals</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline Xerostomia Inventory Score at 3 months</measure>
    <time_frame>Change from baseline Xerostomia Inventory Score at 3 months</time_frame>
    <description>Change from baseline Xerostomia Inventory Score at 3 months. An international validated questionnaire of dry mouth symptoms ranging from 11 to 55 points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline activity of DNAse I enzyme in saliva at 3 months</measure>
    <time_frame>Change from baseline activity of DNAse I enzyme in saliva at 3 months</time_frame>
    <description>Change from baseline activity of DNAse I enzyme in saliva at 3 months measured by Enzyme-Linked Immunosorbent Assay (ELISA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline interleukin-1b (IL-1b) concentration in saliva at 3 months</measure>
    <time_frame>Change from baseline interleukin-1b (IL-1b) concentration in saliva at 3 months</time_frame>
    <description>Change from baseline interleukin-1b (IL-1b) concentration in saliva at 3 months measured by Luminex Assay.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Sjogren's Syndrome</condition>
  <arm_group>
    <arm_group_label>pSS patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>We will evaluate 40 patients with pSS (EULAR/ACR Classification Criteria, 2016) of both sexes before and after periodontal disease treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy individuals</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>We will evaluate 40 healthy controls before and after periodontal disease treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Periodontal scaling</intervention_name>
    <description>Periodontal scaling and root planing</description>
    <arm_group_label>Healthy individuals</arm_group_label>
    <arm_group_label>pSS patients</arm_group_label>
    <other_name>Clinical periodontal disease treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with primary Sjögren's syndrome according to 2016 EULAR/ACR Classification&#xD;
             Criteria, and healthy people without any rheumatic disease/symptoms of sicca syndrome&#xD;
&#xD;
          -  Patients regularly followed at the Sjögren's Syndrome outpatient clinic of&#xD;
             Rheumatology Division&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of drugs that cause oral dryness (mainly antidepressants and antihistamines).&#xD;
&#xD;
          -  Patients with history of head and neck radiation therapy.&#xD;
&#xD;
          -  Current smoking.&#xD;
&#xD;
          -  Pregnancy and/or lactation.&#xD;
&#xD;
          -  History of periodontal treatment for at least 6 months prior to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina da USP</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina da USP</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Ambrósio LM, Rovai ES, França BN, Balzarini DA, Abreu IS, Lopes SB, Nunes TB, Lourenço SV, Pasoto SG, Saraiva L, Holzhausen M. Effects of periodontal treatment on primary sjȫgren's syndrome symptoms. Braz Oral Res. 2017 Jan 16;31:e8. doi: 10.1590/1807-3107BOR-2017.vol31.0008.</citation>
    <PMID>28099577</PMID>
  </results_reference>
  <results_reference>
    <citation>Nakamura-Kiyama M, Ono K, Masuda W, Hitomi S, Matsuo K, Usui M, Nakashima K, Yokota M, Inenaga K. Changes of salivary functions in experimental periodontitis model rats. Arch Oral Biol. 2014 Feb;59(2):125-32. doi: 10.1016/j.archoralbio.2013.11.001. Epub 2013 Nov 8.</citation>
    <PMID>24370183</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 3, 2018</study_first_submitted>
  <study_first_submitted_qc>October 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2018</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

